MedTrace Logo

The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR

NCT02493582 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2016-02-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of Apatinib combined with cytokine-induced killer cell (CIK) vs Apatinib alone as the third line therapy for advanced lung adenocarcinoma patients with wild-type EGFR

Conditions

  • Adenocarcinoma of Lung

Interventions

BIOLOGICAL

Cytokine-Induced Killer Cells

CIKs are used with Apatinib to treat lung adenocarcinoma patients with wild-type EGFR

DRUG

Apatinib

Advanced lung adenocarcinoma patients with wild-type EGFR take Apatinib 850mg qd by mouth.

Sponsors & Collaborators

  • The First People's Hospital of Changzhou

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2030-07-31
Completion
2033-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02493582 on ClinicalTrials.gov